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Adenomyosis is a hormone-related disease that affects 10e66% of women, and womenwith this disorder
suffer from menorrhagia, dysmenorrhea, pelvic pain, abnormal uterine bleeding, and/or infertility.
Regarding the etiology of the disease, the current trend of thought is that adenomyosis or adenomyoma
results as a down-growth and invagination of the endometrial basalis into the adjacent myometrium
after disruption of the normally intact boundary between the two. The eutopic endometrium of ade-
nomyosis presents invasive characteristics, including increased angiogenesis and proliferation, decreased
apoptosis, induction of the local production of estrogens, induction of progesterone resistance, and
impaired cytokine expression, and these changes enhance the ability of the endometrium to inﬁltrate the
junctional zone myometrium and the growth of ectopic tissue. Hysterectomy is the major strategy to
relieve secondary dysmenorrhea caused by adenomyosis. However, fertility and uterine preservation are
compromised by such treatment. The traditional pharmacological therapies for adenomyosis are pri-
marily aimed at the suppression of endogenous estrogen production, but the results are not satisfactory.
Thus, there is an urgent need to develop novel treatment strategies for adenomyosis. There has been
evidence that indicates that the estrogen-induced epithelialemesenchymal transition (EMT) may play a
role in the development of adenomyosis. In this article, we will concentrate on the estrogen-induced
EMT in the pathogenesis of adenomyosis.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Adenomyosis is a common gynecologic disorder that affects
10e66% of women, and women with adenomyosis often present
with menorrhagia, dysmenorrhea, pelvic pain, abnormal uterine
bleeding, and/or infertility.1 The disorder is deﬁned as the presence
of ectopic endometrial glandular and stromal cells located 2.5 mm
below the endometrial-myometrial interface with surrounding
myometrial hyperplasia and hypertrophy.2e4 In the past, the termics and Gynecology, Taipei
University, 201, Section 2,
.
for Gynecologic Endoscopy and Minim“adenomyoma’’ was used to describe this type of lesion. Until 1925,
2 years before Sampson5 created the term “endometriosis” to
represent the presence of uterine mucosa in the peritoneal cavity,
Frankl6 used the term ‘‘adenomyosis’’ to describe the direct
connection of the endometriumwith the islands of mucosa located
in the musculature. Frankl6 deﬁned the term “adenomyosis uteri”
and explained that “I have chosen the name of adenomyosis, which
does not suggest any inﬂammatory genesis as do terms like ade-
nometritis, adenomyositis, and adenomyometritis”. In 1972, Bird2
provided the current deﬁnition of adenomyosis as “adenomyosis
may be deﬁned as the benign invasion of endometrium into the
myometrium, producing a diffusely enlarged uterus which micro-
scopically exhibits ectopic non-neoplastic, endometrial glands and
stroma surrounded by the hypertrophic and hyperplastic
myometrium”.7ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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dysmenorrhea caused by adenomyosis. However, fertility and
uterine preservation are compromised by such treatment.
Removing adenomyotic lesions instead of hysterectomy is another
strategy to treat adenomyosis,8,9 however, the effect is temporary,
and most women quickly develop adenomyosis and must undergo
hysterectomy within 1 year. Even if a normal pregnancy is achieved
after removing adenomyotic lesions, safety remains a major
concern during pregnancy. Residual adenomyosis in the myome-
trium combined with the possible inhibition of pregnancy-related
changes, such as uterine softening, may increase the risk of
miscarriage or uterine rupture. Traditional pharmacological thera-
pies for adenomyosis are primarily aimed at the suppression of
endogenous estrogen production by the application of GnRH ago-
nists and low-dose oral contraceptives.10 However, the results are
not satisfactory. Thus, there is an urgent need to develop novel
treatment strategies for adenomyosis.11
The pathogenesis of adenomyosis still remains unclear, and
there are several postulated mechanisms of pathogenesis: invagi-
nation of basal endometrium, local hyperestrogenism, and me-
chanical forces manifesting as hyper or dysperistalsis.3,4,12e16
Recently, there have been several studies that proposed that the
estrogen-induced epithelialemesenchymal transition (EMT) may
play a role in the development of adenomyosis.17e19 EMT is a
process by which epithelial cells lose their polarity and are con-
verted to a mesenchymal phenotype that is crucial in embryo-
genesis, ﬁbrosis, and tumor metastasis.20 In this review, we will
concentrate on the pathogenesis of adenomyosis, which is related
to EMT.
Pathogenesis of adenomyosis: Invagination of the basal
endometrium
The current deﬁnition of adenomyosis is the benign invasion of
the endometrium into the myometrium, producing a diffusely
enlarged uterus, which microscopically exhibits ectopic non-
neoplastic, endometrial glands, and stroma surrounded by the
hypertrophic and hyperplastic myometrium.2,7 Brosens et al21
demonstrated on a magnetic resonance image (MRI) that there
were two distinct zones: the submucosal layer, also called the
inner myometrium (IM) or junctional zone (JZ), and the outer
myometrium (OM). The JZ is not only structurally different but
also functionally different from the outer myometrium. The
irregular thickening of the JZ has been postulated as the magnetic
resonance criterion for the diagnosis of adenomyosis. Brosens
et al21 postulated that this magnetic resonance appearance relies
on the disruption of the inner myometrial architecture secondary
to smooth muscle hyperplasia. Adenomyosis can also be diag-
nosed by three-dimensional (3D) ultrasonography, which reveals
irregular thickening of the JZ associated with adenomyosis.
Disruption of the speciﬁc microenvironment in the basal endo-
metrium may also explain the structural and functional abnor-
malities of the JZ, such as hyperperistalsis, dysperistalsis, and
inordinate smooth muscle proliferation associated with endo-
metriosis and adenomyosis.22e24
Several human and experimental studies proposed that ade-
nomyosis occurs by invagination of the basal endometrium into the
JZ.25 On imaging, abnormal thickening of the subendometrial
myometrium includes basal endometrium and the JZ. The JZ may
represent a region of structural weakness and myometrial
dysfunction of varying severity susceptible to an invagination of the
stromal cells.25 Following the invagination of stromal cells, invasion
of glandular cells, abnormal growth, and differentiation, these cells
are subsequently surrounded by hypertrophic and hyperplastic
myometrium.26These data suggest that adenomyosis may be caused by defects
in the formation of the JZ of the uterus and that invagination of the
endometrium may play a role in the pathogenesis of adenomyosis.
Chronic inﬂammation and angiogenesis in adenomyosis
Chronic inﬂammation plays a crucial role in the pathogenesis of
adenomyosis, as the presence of ectopic lesions is associated with
the overproduction of prostaglandins, cytokines, and chemo-
kines.3,27 Abundant macrophages inﬁltrating the ectopic lesion
express typical manifestations of facilitating growth and promoting
neuroangiogenesis. In the peritoneal ﬂuid of patients with endo-
metriosis, there is a unique protein, ENDO-1, which is similar to
haptoglobin that can bind to the macrophages and reduce their
phagocytic ability. Furthermore, after binding to ENDO-1, the
macrophages produce more interleukin-6 (IL-6).28 Other increased
cytokines include macrophage migration inhibitory factor (MIF),
tumor necrosis factor-a (TNF-a), IL-1b, IL-8, regulated on activation
normal T expressed and secreted (RANTES), and monocyte
chemotactic protein-1 (MCP-1). Among these cytokines, IL-8,
RANTES, and MCP-1 also act as chemoattractants, which facilitate
the recruitment of macrophages and cause subsequent abundant
peritoneal cytokine accumulation (Fig. 1)3,27,29
Aberrant prostaglandin accumulation also plays a role in the
disease pathogenesis as well as in the clinical manifestations of
dysmenorrhea, chronic pelvic pain, and infertility. Peritoneal
macrophages from women with endometriosis express higher
levels of cyclo-oxygenase-2 (COX-2) and release signiﬁcantly higher
amounts of prostaglandins than macrophages from healthy
women.30 In the microenvironment at the ectopic lesions, TNF-a
promotes endometrial cell production of prostaglandin F2a
(PGF2a) and PGE2.31 The IL-1b activation of COX-2 increases pro-
duction of PGE2, which subsequently activates steroidogenic acute
regulatory protein (StAR) and aromatase. Therefore, estrogen
completes a positive feedback loop that induces the local hyper-
estrogenism by upregulating PGE2 synthesis. This pathway high-
lights the interplay of estrogen dependence and inﬂammation in
the disease pathogenesis.32,33 Moreover, the macrophage nuclear
factor-kappa B (NF-kB)-dependent pathway is also involved in the
pathogenesis and induces the subsequent transactivation of con-
trolling angiogenesis and tissue remodeling.34,35
Increased invasiveness
Adenomyosis can be diagnosed by imaging studies withMRI and
3D ultrasonography, onwhich there is irregular thickening of the JZ
and the so-called inner myometrium that is associated with ade-
nomyosis.22,23 Several human and experimental studies proposed
that adenomyosis occurs by invagination of the basal endometrium
into the inner layer of the IM known as the JZ.25 On imaging,
abnormal thickening of the subendometrial myometrium includes
the basal endometrium and the JZ. The JZ may represent a region of
structuralweakness andmyometrial dysfunction of varying severity
that is susceptible to an invaginationof the stromal cells.25 Following
invagination of the stromal cells, invasion of glandular cells,
abnormal growth, and differentiation, these cells are subsequently
surroundedbyhypertrophic andhyperplasticmyometrium.26 These
ﬁndings from imaging studies suggest that adenomyosis may be
caused by defects in the formation of the JZ of the uterus.
Moreover, the increased invasiveness of the endometriotic cells
lends weight to the basal endometrium invagination hypothesis.36
The nonmalignant invasive endometriotic cells were identiﬁed as
lacking the tumor suppressor molecule, E-cadherin, in contrast to
the eutopic endometrium.37 Benagiano and Brosens38 suggested
that the eutopic endometrium of adenomyosis presented more
Fig. 1. A model of the most relevant molecular pathways involved in the pathophysiology of adenomyosis. COX-2 ¼ cyclooxygenase-2;EMT ¼ Epithelialemesenchymal transition;
IL ¼ interleukin; NFkb ¼ nuclear factor kappa b; MCP ¼monocyte chemotactic protein-1; MIF ¼macrophage migration inhibitory factor; RANTES ¼ regulated on activation normal
T expressed and secreted; TNF ¼ tumor necrosis factor; VEGF ¼ vascular endothelial growth factor.
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proliferation, decreased apoptosis, induction of the local produc-
tion of estrogens, induction of progesterone resistance, and
impaired cytokine expression and that these changes enhanced the
ability of the endometrium to inﬁltrate the JZ myometrium and the
growth of ectopic tissue. In vitro, the adenomyotic stromal cells
possessed greater invasiveness compared with normal endometrial
stromal cells.38 The invasiveness of normal endometrial stromal
cells could be enhanced by the adenomyotic myocytes in a cocul-
ture model.39 Thus, both stromal cells and myocytes may
contribute to the pathogenesis of adenomyosis and reﬂect a whole
uterine abnormality.39
Role of estrogen in the pathogenesis of adenomyosis
Estrogens inﬂuence many physiological processes and systems
in mammals, including reproduction, the cardiovascular system,
bone density, cognition, and behavior. Given this widespread role of
estrogen in human physiology, it is not surprising that estrogen is
also implicated in the development or progression of numerous
diseases, which include but are not limited to various types of
cancer (breast, ovarian, colorectal, prostate, and endometrial can-
cers), osteoporosis, leiomyoma, neurodegenerative diseases, car-
diovascular disease, insulin resistance, lupus erythematosus,
endometriosis, and obesity.40 There are two main isoforms of es-
trogen receptors (ERs), ER-a and ER-b, which are encoded by
separate genes, Esr1 and Esr2, respectively.
The pathogenesis of adenomyosis is considered an estrogen-
related disorder, and a local rather than systemic hyper-
estrogenism may be implicated.41 There is evidence that local
hyperestrogenism results from the action of aromatase on
androgen precursors42; aromatase mRNA is localized in adenomy-
otic tissue homogenate, and the aromatase protein is localized in
the adenomyotic glands.43 The aforementioned ﬁndings may be the
reason that a higher estrogen level is detected in menstrual blood
but not peripheral blood in women with adenomyosis.44Moreover, the deﬁcient methylation of the ER-b promoter re-
sults in the pathological overexpression of ER-b in endometriotic
stromal cells. Thus, high levels of ER-b suppress ER-a expression,
and a severely high ERb-to-ERa ratio in endometriotic stromal cells
is associated with decreased progesterone receptor (PR), particu-
larly PR-B, and increased cyclo-oxygenase-2 (COX-2) levels,
contributing to progesterone resistance and inﬂammation.
Decreased PR expression may be associated with progesterone
resistance.45,46 In the normal endometrium, progesterone pos-
sesses an antiestrogen activity, in part by inducing 17b-hydrox-
ysteroid dehydrogenase 2 (HSD17B2), which catalyzes the
conversion of biologically potent estradiol (E2) to the less estro-
genic estrone (E1).47,48 Progesterone stimulates progesterone re-
ceptors in endometrial stromal cells to increase the formation of
retinoic acid, which in turn induces HSD17B2 expression in endo-
metrial epithelial cells in a paracrine fashion.49 However, endo-
metriotic stromal cells represent a limited response to
progesterone and the production of retinoic acid. In endometriotic
tissue, decreased retinoic acid levels lead to decreased epithelial
HSD17B2 and the failure to suppress estradiol levels.50 Thus,
combined with high local estradiol production due to aberrant
aromatase activity, this additional defect contributes to the
abnormally high levels of estradiol in endometriotic tissue.
The expression levels of ER and PR isoforms during the men-
strual cycle in eutopic and ectopic endometrium in women with
adenomyosis were evaluated in an immunohistochemical study,
and there was a signiﬁcant decrease in ER-a expression during the
midsecretory phase of the menstrual cycle in the adenomyotic
functionalis glands and stroma. However, the expression of ER-a in
the inner and outer myometrium was not signiﬁcantly different in
the adenomyotic functionalis glands and stroma. By comparison,
the ER-b expression was signiﬁcantly elevated in the adenomyotic
functionalis gland during the proliferative phase and throughout
the myometrium across the entire menstrual cycle.51 Expression
of PR-A is similar to that of PR-B, with reduced expression in the
basalis stroma and the inner and outer myometrium in
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similar in the endometrium basalis and adenomyotic foci. Higher
ER-b expression and the lack of PR expression may be related to the
pathogenesis of adenomyosis and provides evidence to explain the
poor response of adenomyosis to progestational agents.51
EMT in adenomyosis
Epithelial cells are initiated to convert to migratory and invasive
cells during the EMT. This process has been considered to be a
fundamental event in morphogenesis, as it is intimately involved in
the generation of tissues and organs during embryogenesis in both
vertebrates and invertebrates. A similar process is represented
during wound healing, a classic example of a process in adulthood
in which EMT is crucial.52 During EMT, epithelial cells lose their
expression as epithelial markers (e.g., E-cadherin and plakoglobin),
acquire mesenchymal marker expression (e.g., N-cadherin and
vimentin), and gain increased migratory and invasive capabilities.
Furthermore, several studies have shown that tumor cells may
undergo EMT to facilitate cellular invasion, which can be stimulated
either by extracellular cytokines, such as TGF-b, EGF, and FGF, or by
intracellular cues, such as oncogenic Ras or NFkB signaling.53 Then,
EMT is initiated by a number of transcription factors that target the
CDH1 gene promoter and repress the expression of E-cadherin.54
These transcriptional repressors include Snail (Snail1), Snail2
(Slug), Twist1, Zeb1, Zeb2, Goosecoid, FOXC2, FoxQ1, KLF8, and Prrx.
Thus, these EMT master regulators also induce tumor metastasis
through inducing the cancer stem-cell phenotype, blocking
oncogene-induced senescence and suppressing the host immune
surveillance system.20,53,54
At an initial stage in cancer metastasis, tumor cells need to gain
the ability to disseminate from a solid tumor mass and invade the
surrounding stromal tissues, either as a group of cells (cohesive
migration) or as single cells (mesenchymal invasion or amoeboid
invasion).55 This phenomenon has been conﬁrmed in several
in vitro cancer cell line studies.56,57 Moreover, in the analysis of
clinical patient samples, EMT among cancer cells in the invasive
front of a number of different tumor types was demon-
strated,56,58,59 which may be crucial for tumor cell dissemination
and metastasis.58,60e62
However, during the embryogenesis of the urogenital system,
the endometrium is derived from intermediate mesoderm via the
mesenchymal-to-epithelial transition (MET). By preserving some
imprint of their mesenchymal origin, the endometrial epithelial
cells may be particularly prone to return to this state, via EMT.52
Previous studies have demonstrated that E-cadherin-negative
epithelial cells were increased in peritoneal endometriosis
compared with eutopic endometrium and that E-cadherin-nega-
tive, N-cadherin-positive endometriotic epithelial cells were inva-
sive in vitro.37,63
Moreover, the tissue remodeling process may play a role in the
pathogenesis of adenomyosis, and van Kaam et al64 demonstrated
that the presence of adenomyotic nodules in deeply inﬁltrating
endometriosis lesions is accounted for by a reaction of the local
environment to the presence of ectopic endometrium.64 The tis-
sue injury and repair (TIAR) theory was postulated by Leyen-
decker et al.65 The wound healing process involves more
extensive tissue remodeling through production of extracellular
matrix (ECM) components, remodeling enzymes, cellular adhe-
sion molecules, growth factors, cytokines, and chemokine genes.
Activated macrophages generate various cytokines, including
transforming growth factor (TGF)-b, which promotes tissue
remodeling and subsequently causes ﬁbroblasts to differentiate
into myoﬁbroblasts. Stromal cells were characterized as myoﬁ-
broblasts due to their expression of a-smooth muscle actin,tropomyosin, desmin, and collagens.66 Myoﬁbroblasts play an
important role in the development of adenomyosis by their
expression of ECM proteins. These data suggest that myometrial
hypertrophy is a response/reaction of the ectopic endometrial
cells to the surrounding tissue, which shares characteristics with
the physiological and pathological mechanisms of wound
healing.
Furthermore, the extensive regulation, remodeling, and cyclical
shedding of endometrial tissue requires the activation of matrix
metalloproteinases (MMPs), which may contribute to the patho-
genesis of adenomyosis. Gurates and Bulun67 suggested that MMPs
mediate endometrial breakdown and assist with new endome-
trium under the stimulation of estrogen. Most MMPs are under the
inﬂuence of estrogen and progesterone: they are upregulated by
estrogen and downregulated by progesterone.68 Furthermore,
compared with eutopic endometrium, ectopic endometrium
possessed more tissue remodeling and endometrial invasion-
involved activation of MMPs by extracellular matrix metal-
loproteinase inducer (EMMPRIN).68 In one immunochemical anal-
ysis of uterine EMMPRIN, ER and PR expression throughout the
menstrual cycle, the expression of EMMPRIN was strongest during
the proliferative phase, while ER and PR were maximally expressed
concomitantly.69 Thus, the expression of EMMPRIN may be
involved in the upregulation of MMPs, which enhances the endo-
metrial invasive capability.
There is evidence that there is invasive behavior and cytoskel-
etal rearrangement in endometrial epithelial cells during endo-
metriotic tissue implantation.63 Compared with normal controls, E-
cadherin is reduced in the uterine epithelial cells of women with
endometriosis.64 E-cadherin expression is further decreased in
ectopic endometriotic lesions. The upregulation of vimentin
expression was shown in endometriotic lesions compared with
normal uterine endometrium.70e72
Estrogen-related EMT has been demonstrated through the
upregulation of Snail or Slug in several tumor cell studies, such as in
ovarian and breast cancers.73 As a result, Chen et al17 postulated
that estrogen-induced EMT may be involved in the pathogenesis of
adenomyosis, due to the invasive behavior and cytoskeletal rear-
rangement of endometrial epithelial cells and that the effect of
estrogen-induced EMT could be abrogated by raloxifen, a selective
estrogen receptor modulator. Zhou et al18 demonstrated that
through estrogen stimulation, there was upregulation of annexin
A2, which was correlated with the expression of EMT markers in
ectopic adenomyotic lesions and the severity of dysmenorrhea in
women with adenomyosis. The upregulation of annexin-A2
expression could mediate phenotypic mesenchymal-like cellular
changes, with structural and functional alterations in a b-catenin/T-
cell factor (Tcf) signaling-associated manner, which could be
reversed by the inhibition of annexin A2 expression. Moreover,
annexin A2 enhanced the proangiogenic capacity of adenomyotic
endometrial cells through the HIF-1a/VEGF-A pathway.18 Oh et al19
further proved that the b-catenin activation caused induction of
Snail and ZEB1 expression, repression of E-cadherin expression,
and induction of mesenchymal cell marker expression in endo-
metrial epithelial cells during the pathogenesis of adenomyosis. In
human adenomyotic lesions, CD10, a useful molecule of tumor in-
vasion, was expressed compared with the negative result of normal
controls. Moreover, in the adenomyotic mouse model with over-
expression of b-catenin, the upregulation of COUP-TFII, which was
associated with the induced extracellular matrix-degrading pro-
teinases MMP2 and urokinase-type plasminogen activator (uPA),
was noted in some cells.19 MMP2 and uPA are known to play critical
roles in angiogenesis and metastasis.19 Thus, estrogen-induced
tissue remodeling and EMT may be involved in the pathogenesis
of adenomyosis.
B.-S. Huang et al. / Gynecology and Minimally Invasive Therapy 4 (2015) 55e60 59There is conclusive evidence that estrogen, particularly through
stimulating ER-b, upregulates tissue remodeling and the EMTof the
basal endometrium, and these processes are also associated with
local inﬂammatory processes and angiogenesis. Thus, ERb-selective
estradiol antagonists may provide a novel treatment for adeno-
myosis in the future.
Conclusion
Adenomyosis is considered a hormone-related disorder, and
through estrogen stimulation, particularly ER-b, EMT is induced in
the basal endometrium resulting in invagination into the myome-
trium surrounded by hypertrophic myometrium.
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